Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Breast Cancer 1HER2 Overexpression 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Isovaleryl-CoA Dehydrogenase × 1 year × Clear all
NCT07281001 2025-12-15

Traderrus

Blokhin's Russian Cancer Research Center

Phase NA Recruiting
60 enrolled
Breast

HER2-positive Breast Cancer

NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡